Naarden, The Netherlands, 2nd April 2007 – BAC BV, the Bio Affinity Company announced today that it has entered into a collaboration with GE Healthcare, a unit of General Electric Company (NYSE: GE), to develop and market affinity chromatography media for the purification of therapeutic recombinant FVIII. BAC will provide its CaptureSelect® affinity ligands, renowned for their high stability and specificity, to enable efficient process-scale purification of FVIII for the prevention and treatment of bleeding in patients with Haemophilia A.
